Association of Influenza Vaccination With SARS-CoV-2 Infection and Associated Hospitalization and Mortality Among Patients Aged 66 Years or Older

Abstract

ImportanceVaccine effectiveness studies have rarely implemented strategies to reduce the healthy vaccinee bias arising from differences in health care–seeking behavior between vaccinated and unvaccinated individuals. Although previous observational studies suggest that influenza vaccination is associated with a reduced risk of SARS-CoV-2–associated outcomes, the healthy vaccinee bias may have led to overestimating the vaccination effect.ObjectiveTo estimate the association between influenza vaccination and SARS-CoV-2–associated outcomes.Design, Setting, and ParticipantsThis cohort study was conducted over 2 consecutive influenza vaccination campaigns (2019-2020 and 2020-2021), owing to the substantial COVID-19 burden and the greater validity of influenza vaccination data in the studied age group. The study population included community-dwelling adults aged 66 years or older in Ontario, Canada.ExposureInfluenza vaccination for a given season.Main Outcomes and MeasuresThe outcomes of interest included SARS-CoV-2 infection, SARS-CoV-2–associated hospitalization, SARS-CoV-2–associated death, and a composite of SARS-CoV-2–associated hospitalization or death. Cox proportional hazards models were used to measure the association between influenza vaccination and SARS-CoV-2–associated outcomes, censoring individuals who moved into long-term care, received COVID-19 vaccines, or died before the observation period end date. Primary care periodic health examinations (PHEs) were explored as a negative tracer exposure (ie, no association expected with SARS-CoV-2 outcomes) and as an effect modifier of the association between influenza vaccination and SARS-CoV-2 outcomes.ResultsOf 2 922 449 individuals aged 66 years or older (54.2% female) living in Ontario, 2 279 805 were included in the study. Among these, 1 234 647 (54.2%) were female and 1 045 158 (45.8%) were male; their mean (SD) age was 75.08 (7.21) years. Those who had received influenza vaccination exhibited a lower incidence of SARS-CoV-2 infection than unvaccinated individuals for the 2019-2020 cohort (adjusted hazards ratio [aHR], 0.78; 95% CI, 0.73-0.84) and the 2020-2021 cohort (aHR, 0.76; 95% CI, 0.74-0.78). This association was also observed for SARS-CoV-2–associated hospitalization or death (2019-2020: aHR, 0.83; 95% CI, 0.74-0.92; 2020-2021: aHR, 0.66; 95% CI, 0.63-0.70). Similarly, undergoing a PHE was also associated with a lower incidence of SARS-CoV-2 infection (aHR, 0.85; 95% CI, 0.78-0.91) and SARS-CoV-2–associated hospitalization or death (aHR, 0.80; 95% CI, 0.70-0.90), and modified the association between influenza vaccination and SARS-CoV-2 infection for vaccinated individuals who underwent PHE (aHR, 0.62; 95% CI, 0.52-0.74) and for vaccinated individuals who did not undergo PHE (aHR, 0.81; 95% CI, 0.76-0.87), and also SARS-CoV-2–associated hospitalization or death in vaccinated individuals who underwent PHE (aHR, 0.66; 95% CI, 0.49-0.88) and vaccinated individuals who did not undergo PHE (aHR, 0.85, 95% CI, 0.76-0.95).Conclusions and RelevanceThe findings of this cohort study suggest that undergoing a PHE may at least partially modify the association between influenza vaccination and SARS-CoV-2–associated outcomes in individuals aged 66 years or older, providing evidence of the healthy vaccinee bias that may affect vaccine effectiveness studies.

Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study

“…A recent study by Bruxvoort et al showed that recombinant adjuvanted zoster vaccine was associated with a lower risk of COVID-19 diagnosis and lower risk of hospitalization [ 23 ]. Furthermore, Hosseini-Moghaddam et al revealed that among people aged ≥66 years, influenza vaccination was associated with a decreased risk of SARS-CoV-2 infection [ 24 ]. Nevertheless, it remains unclear if these vaccinations induce trained immunity, particularly for COVID-19 protection [ 25 ].…”

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)

“…These results support the safety of co-administration of the two vaccines. A population-based cohort study demonstrated that the influenza vaccination was associated with a 22% to 24% lower risk of SARS-CoV-2 infection, a 17% to 32% lower risk of SARS-CoV-2–associated hospitalization, and a 27% to 42% lower risk of SARS-CoV-2–associated mortality during the first 2 years of the COVID-19 pandemic [ 135 ].…”

Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity

“…There is some indication of a cross-variant neutralizing response to the COVID-19 vaccine. The results are mixed, however some studies suggested that influenza vaccination may attenuate the impact of COVID-19 potentially through a vaccine-induced change in innate immunity and a cross-reactivity response [3] , [4] , [5] , [6] .…”